ImmunoPrecise Antibodies Will Be in San Francisco During J.P. Morgan Healthcare Conference Week January 13-16, 2020HomeMailNewsFinanceSportsEntertainmentSearchMobileMoreYahooSearchNo matching results for ''Tip: Try a valid symbol or a specific company name for relevant resultsSign inMailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)ImmunoPrecise Antibodies Will Be in San Francisco During J.P. Morgan Healthcare Conference Week January 13-16, 2020CNW GroupJanuary 6, 2020ReblogShareTweetShareVICTORIA , Jan. 6, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (IPATF) announced today IPA will be in San Francisco during the J.P. Morgan 38th Annual Healthcare Conference events running from January 13-16, 2020 in San Francisco, California . The annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.View photosImmunoPrecise Antibodies Ltd. (CNW Group/ImmunoPrecise Antibodies Ltd.)MoreThirty-eight years ago, this meeting launched as a boutique event with only 20 companies focused on biotechnology. Now it attracts more than 450 companies, both public and private, to deliver presentations to more than 9,000 attendees. Global thought leaders and biotech industry experts share their ideas and strategies with investors to reshape the industry.Jennifer Bath , ImmunoPrecise President and CEO, Frederic Chabot , Investor Relations, and Brian Lundstrum , Director, will be taking investor and business development meetings throughout the conference. To request a meeting please email
Sue LeGare .About ImmunoPrecise Antibodies Ltd.ImmunoPrecise is an international, full-service, therapeutic antibody discovery company offering species agnostic advancements such as the B cell Select™ progressive, single-cell interrogation technology and the DeepDisplay™ custom phage libraries, as well as the Abthena™ bispecific program. IPA is focused on the next generation of antibody discovery, to deliver the most therapeutically relevant antibodies, in a shorter timeframe, with the highest probability of succeeding to clinical trials. ImmunoPrecise's discovery and development are conducted in Utrecht and Oss, the Netherlands (U-Protein Express and IPA Europe, respectively), and in Victoria, British Columbia (IPA Canada). The Company operates globally to offer a continuum of superior antibody services, transforming the face of therapeutic discovery, by decreasing turnaround time and risk, and promoting clinical success.Forward Looking InformationThis news release contains statements that, to the extent they are not recitations of historical facts, may constitute "forward-looking statements" within the meaning of applicable Canadian securities laws. The Company uses words such as "may", "would", "could", "will", "likely", "expect", "believe", "intend" and similar expressions to identify forward-looking statements. Any such forward-looking statements are based on assumptions and analyses made by ImmunoPrecise in light of its experience and its perception of historical trends, current conditions and expected future developments. However, whether actual results and developments will conform to ImmunoPrecise's expectations and predictions is subject to any number of risks, assumptions and uncertainties. Many factors could cause ImmunoPrecise's actual results to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors include, among other things, actual revenues and earnings for ImmunoPrecise being lower than anticipated, and those risks and uncertainties described in ImmunoPrecise's annual management discussion and analysis for the fiscal period ended October 31, 2019 which can be accessed at www.sedar.com. The "forward-looking statements" contained herein speak only as of the date of this press release and, unless required by applicable law, ImmunoPrecise undertakes no obligation to publicly update or revise such information, whether as a result of new information, future events or otherwise.Story continuesSOURCE ImmunoPrecise Antibodies Ltd.View photosView original content to download multimedia: http://www.newswire.ca/en/releases/archive/January2020/06/c4036.htmlReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextFacebook Cancels Annual Conference Due to Coronavirus Concerns: 'This Was a Tough Call to Make'People'Dispatches From Elsewhere': a crazy real-life 'game' comes to TVAFPRegulators boost PG&E's wildfire fine to $2.1 billionAssociated PressWould You Live in an Adult Dorm? One Silicon Valley Startup Is Renting Out Shared RoomsHouse BeautifulBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoMost face masks won’t protect you from the coronavirusYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoKey Things To Watch Out For If You Are After Evli Pankki Oyj's (HEL:EVLI) 5.8% DividendSimply Wall St.Stock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloomberg'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoDell Technologies (DELL) Matches Q4 Earnings EstimatesZacks